Article Text
Abstract
Introduction/Background To evaluate the mismatch repair (MMR) protein expression in endometrial cancer and to assess their association with clinico-pathologic outcomes.
Methodology A retrospective review of the clinico-pathologic data and clinical outcomes was performed on patients who were treated for endometrial cancer at a single center between 2014 and 2018. For the study analysis, patients with results for MMR protein immunohistochemistry were included. MMR-deficient (MMR-d) was defined as absence of expression in any of the 4 MMR proteins (MLH1, MSH2, MSH6, and PMS2). Clinical and pathologic outcomes were compared according to the MMR status.
Results A total of 146 endometrial cancer patients with available MMR expression data were included. Of these, 41 patients (28.1%) showed absence of MMR protein expression (MMR-d). Compared with MMR-proficient (MMR-p) patients, the MMR-d patients had higher rate of pelvic and/or para-aortic lymph node metastasis and lymphovascular space invasion (p=0.011 and p=0.015, respectively). However, other clinico-pathologic variables, including stage, grade, histologic subtype, and depth of invasion, were not associated with MMR status. During the median follow-up period of 18.2 months (1–39.4), there was no difference in progression-free survival between MMR-p and MMR-d patients (p=0.181).
Conclusion MMR defects were associated with higher rate of lymphovascular space invasion and lymph node metastasis. However, other prognostic factors and survival outcomes were not different between MMR-p and MMR-d patients.
Disclosure Nothing to disclose.